Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- FDA Approves World’s First MEK Inhibitor Discovered by JT
May 31, 2013
- Members of Study Group Say Ban on Use of Medical Information Database by Drug Makers Should Be Reconsidered After Trial Period Ends
May 31, 2013
- Expert Subcommittee to Begin Discussing Cost-Effective Assessments for Specific Medical Technologies
May 31, 2013
- H. pylori Eradication Could Greatly Reduce Medical Expenditure; Manufacturers of PPIs Will Need to Educate the Public
May 31, 2013
- Outline of Growth Strategy Embraces Japan-Version NIH, Promotion of Special System for Mixed Healthcare
May 30, 2013
- 45 Face-to-Face Consultation Meetings Provided through PMDA’s Regulatory Strategy Consultation Service as of March 2013
May 30, 2013
- MHLW Reprimands Novartis over Diovan Papers
May 29, 2013
- Report of MOF’s Fiscal System Council Calls for 100% Generic Share Target
May 29, 2013
- PAFSC’s Second Committee Recommends Approval for IV Preparation of Acetaminophen
May 28, 2013
- First Committee Recommends Approval for Third GLP-1 Receptor Agonist Lyxumia, Others
May 27, 2013
- “Strong Guidance Will Be Required” in Diovan Case: Health Minister Tamura
May 27, 2013
- Citations in Guidelines to Be Prerequisite for Health Coverage of Off-Label Drugs under 1980 Notification
May 24, 2013
- New Rules to Promote Generic Drug Use by Welfare Recipients to Take Effect This Year
May 23, 2013
- MOF Official Expresses Caution on Perpetuation of New Drug Premium, Citing “Need for Continual Verification”
May 22, 2013
- MHLW Orders Marketing Authorization Holders of Careram/Kolbet to Issue a “Blue Letter”
May 21, 2013
- PM Abe Indicates that Next Fiscal Reform Plan Will Not Include Controls on Growth Rate of Social Security Spending
May 20, 2013
- NIBIO Establishes Center for Innovative Drug Discovery and Development, Appoints Yoichi Kurebayashi as Director
May 20, 2013
- 39 Companies Report Discontinuing Supplies of Generics within 5 Years: MHLW Survey
May 17, 2013
- Government Aims for 60% Generic Drug Share by End of FY2017; Some See Shortcomings in Roadmap
May 17, 2013
- Pharma Execs Call for Perpetuation of Premium at 1st Public-Private Dialogue under PM Abe’s Second Cabinet
May 16, 2013
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…